Collaboration for rare diabetes: understanding new treatment options for Wolfram syndrome
- 1 March 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Endocrine
- Vol. 71 (3), 626-633
- https://doi.org/10.1007/s12020-021-02622-3
Abstract
Background Wolfram Syndrome is a very rare genetic disease causing diabetes mellitus, blindness, deafness, diabetes insipidus, and progressive brainstem degeneration. Neurologic symptoms of affected patients include ataxia, sleep apnea, loss of bladder control, dysphagia, loss of taste, and accompanying psychiatric symptoms as a sign of progressive neurodegeneration. Its genetic cause is mainly biallelic mutations of the Wolframin endoplasmatic reticulum transmembrane glycoprotein gene Wfs1. These result in increased ER stress, which in turn induces apoptosis and leads to the depletion of the corresponding cells and a loss of their physiological functions. Though diabetes mellitus is mostly treated by insulin, there is still no proven cure for the disease in general. It leads to premature death in affected individuals-usually within the 4th decade of live. Current research and treatment trials Clinical studies are currently being conducted at various locations worldwide to test a therapy for the disease using various approaches. Potentail of virtual netowrking As rare diseases in general represent a major challenge for individual clinicians and researchers due to the rarity of diagnosis, the lack of evidence and of value of existing research, international cooperation, coordination and networking leading to an alignment of different stakeholders is necessary to support patients and increase knowledge about these diseases, like wolfram syndrome. Conclusion ENDO-ERN and EURRECA are two EU-funded networks that aim to promote knowledge sharing, education and research on rare endocrine diseases.Keywords
This publication has 47 references indexed in Scilit:
- Genotypic classification of patients with Wolfram syndrome: insights into the natural history of the disease and correlation with phenotypeGenetics in Medicine, 2013
- Diabetes and Neurodegeneration in Wolfram SyndromeDiabetes Care, 2011
- Wfs1 mutation makes mice sensitive to insulin-like effect of acute valproic acid and resistant to streptozocinJournal of Physiology and Biochemistry, 2011
- Neurologic features and genotype‐phenotype correlation in Wolfram syndromeAnnals of Neurology, 2010
- Wolfram syndrome and WFS1 geneClinical Genetics, 2010
- Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cellsJCI Insight, 2010
- Wolfram syndrome: important implications for pediatricians and pediatric endocrinologistsPediatric Diabetes, 2010
- Valproate, a Mood Stabilizer, Induces WFS1 Expression and Modulates Its Interaction with ER Stress Protein GRP94PLOS ONE, 2009
- WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic β-cellsHuman Molecular Genetics, 2006
- Mutation analysis of the WFS1 gene in seven Danish Wolfram syndrome families; four new mutations identifiedEuropean Journal of Human Genetics, 2005